



New approaches in pharmacologic treatment of congestive heart failure, coronary disease, hypertension, orthostatic hypotension and diabetes

Gary L Murray

Heart and Vascular Institute, USA

Abstract

The first, easily employed method of independently measuring Parasympathetic(P) and Sympathetic(S) heart rate variability, which will be described, has been invaluable in our discovering that ranolazine improves left ventricular ejection fraction in 70% of CHF patients on average 11 EFUs when added to guideline therapy, and also prevents acute coronary syndromes. P and S measures also allowed doubling the control of hypertension, control of orthostatic hypotension in 2/3 of patients and a 31% RRR of sudden death in AODM with alpha lipoic acid. These studies will be discussed in detail.

Gary L Murray graduated from the Tulane School of Medicine in 1974, practicing cardiology ever since. He has published several articles, has been cited in several textbooks, co-invented the Schad Murray RNA exercise test for CAD and the 5 minute IPPA myocardial viability imaging. He is Co-Chairman of the Membership Committee of the International College of Angiology.

Biography

Gary L Murray graduated from the Tulane School of Medicine in 1974, practicing cardiology ever since. He has published several articles, has been cited in several textbooks, co-invented the Schad Murray RNA exercise test for CAD and the 5 minute IPPA myocardial viability imaging. He is Co-Chairman of the Membership Committee of the International College of Angiology.



[7th International Conference on Cardiology and Cardiovascular Medicine](#) | July 14, 2020

Citation: Gary L Murray, *New approaches in pharmacologic treatment of congestive heart failure, coronary disease, hypertension, orthostatic hypotension and diabetes*, Global Cardiology Congress 2020, 7th International Conference on Cardiology and Cardiovascular Medicine, July 14, 2020, pp- 02